Fencamfamin

Fencamfamin
Clinical data
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	N06BA06 (WHO) ;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); CA: Schedule IV; DE: Anlage II (Authorized trade only, not prescriptible); US: Schedule IV;
Pharmacokinetic data
Elimination half-life	16 hours
Identifiers
	IUPAC name N-Ethyl-3-phenyl-norbornan-2-amine;
CAS Number	1209-98-9 ;
PubChem CID	14584;
DrugBank	DB01463 ;
ChemSpider	13922 ;
UNII	NME1I5IGBK;
KEGG	D07343 ;
ChEMBL	ChEMBL7010 ;
CompTox Dashboard (EPA)	DTXSID60862601 ;
Chemical and physical data
Formula	C15H21N
Molar mass	215.340 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNC1C(C2CCC1C2)C3=CC=CC=C3;
	InChI InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3 ; Key:IKFBPFGUINLYQI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fencamfamin (INN), also known as fencamfamine or by the brand names Glucoenergan and Reactivan, is a stimulant which was developed by Merck in the 1960s.^[3]

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Delbeke FT, Debackere M (1981). "Detection and metabolism of fencamfamine and the influence of acetazolamide on its urinary excretion". Biopharmaceutics & Drug Disposition. 2 (1): 17–30. doi:10.1002/bdd.2510020103. PMID 7236868.
^ DE patent 1110159, "Improvements in or relating to Amino-Norcamphane Compounds", issued 1961-07-06, assigned to Merck

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] Delbeke FT, Debackere M (1981). "Detection and metabolism of fencamfamine and the influence of acetazolamide on its urinary excretion". Biopharmaceutics & Drug Disposition. 2 (1): 17–30. doi:10.1002/bdd.2510020103. PMID 7236868.

[3] DE patent 1110159, "Improvements in or relating to Amino-Norcamphane Compounds", issued 1961-07-06, assigned to Merck

[1]

[2]

[3]

Clinical data

Pregnancy category	?
Routes of administration	Oral
ATC code	N06BA06 (WHO)
Legal status
Legal status	BR: Class B1 (Psychoactive drugs)^[1] CA: Schedule IV DE: Anlage II (Authorized trade only, not prescriptible) US: Schedule IV
Pharmacokinetic data
Elimination half-life	16 hours^[2]
Identifiers
IUPAC name N-Ethyl-3-phenyl-norbornan-2-amine
CAS Number	1209-98-9^N
PubChem CID	14584
DrugBank	DB01463^Y
ChemSpider	13922^Y
UNII	NME1I5IGBK
KEGG	D07343^Y
ChEMBL	ChEMBL7010^Y
CompTox Dashboard (EPA)	DTXSID60862601
Chemical and physical data
Formula	C₁₅H₂₁N
Molar mass	215.340 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCNC1C(C2CCC1C2)C3=CC=CC=C3
InChI InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3^Y Key:IKFBPFGUINLYQI-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)